

Opportunistic bone density assessment using pre-treatment [¹⁸F]FDG-PET/CT identifies fracture risk in lymphoma patients undergoing corticosteroid-containing chemotherapy

Authors

Genevieve Douglas,^{1,2} Kane M. Nicholls,^{3,4} Erin Paul,⁴ Zoe Loh,¹ Sze-Ting Lee,^{3,4,5} Kathryn L. Hackman,^{6,7} Cherie Chiang,^{5,8} Niamh Waters,^{1,2} Geoffrey Chong,^{2,5,9} Ashvind Prabakaran^{1,10} and Eliza A. Hawkes^{1,2,5,9,11}

¹Clinical Hematology, Austin Health, Heidelberg; ²Lymphoma Clinical Innovations Group, Olivia Newton John Cancer and Research Institute, Austin Hospital, Heidelberg; ³Radiology Department, Austin Health, Heidelberg; ⁴Department of Molecular Imaging and Therapy, Austin Health, Heidelberg; ⁵Department of Medicine, University of Melbourne, Melbourne; ⁶Department of Endocrinology and Diabetes, Alfred Health, Melbourne; ⁷Department of Medicine, Monash University, Melbourne; ⁸Department of Endocrinology, Austin Health, Heidelberg; ⁹Department of Medical Oncology, Austin Hospital, Heidelberg; ¹⁰Clinical Hematology,

Monash Health, Clayton and ¹¹School of Public Health and Preventative Medicine, Monash University, Melbourne, Victoria, Australia

Correspondence:
G. DOUGLAS - genevieve.douglas2@austin.org.au

<https://doi.org/10.3324/haematol.2024.286618>

Received: September 25, 2024.
Accepted: January 15, 2025.
Early view: January 23, 2025.

©2025 Ferrata Storti Foundation

Published under a CC BY-NC license 

Table S1: Additional lymphoma, prior fracture and treatment characteristics					
Variables		A: Whole cohort		B: L1HU analysis cohort	
Total		n	%	n	%
Total		313	100.0	255	100
Fracture history prior to lymphoma therapy					
Total		37	11.8	24	9.4
Atraumatic		9	2.9	0	0.0
Traumatic		7	2.2	7	2.7
Uncertain trauma level		17	5.4	15	5.9
Pathological		4	1.3	2	0.8
Lymphoma subtype					
DLBCL		268	85.9	213	83.9
cHL		10	3.2	10	3.9
PTCL		2	0.6	2	0.8
Other high-grade lymphoma		28	8.9	26	10.2
Indolent		4	1.3	3	1.2
Missing		1	0.3	1	0.4
First-line treatment delivered					
CHOP +/- rituximab		288	92.0	237	92.9
CVP +/- R		12	3.8	6	2.4
ABVD/escBEACOPP combination		4	1.3	4	1.6
escBEACOPP		1	0.3	1	0.4
Other*		8	2.6	7	2.7
DLBCL=diffuse large B-cell lymphoma; cHL=classical Hodgkin lymphoma; PTCL=peripheral T-cell lymphoma; CHOP=Cyclophosphamide, doxorubicin, vincristine and prednisolone; CVP=cyclophosphamide, vincristine and prednisolone; R=Rituximab; ABVD=doxorubicin, bleomycin, vinblastine, dacarbazine; escBEACOPP=escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisolone, procarbazine					
*Other chemotherapy: PVAG (n=2), DA-R-EPOCH (n=6)					

Table S2: New fracture / any bone event following commencement of lymphoma treatment

[illegible]

Table S3: Detail of fractures identified following commencement of lymphoma therapy

Fracture details		Known OP pre-treatment	No pre-treatment OP
All		4	20
	Vertebral	2	9
	Wrist	1	5
	Ribs	0	2
	Hip	0	1
	Humerus	1	2
	Unknown	0	1

Table S4: Detail of prior malignancies

Prior malignancies	47
Breast cancer	9
Melanoma	8
Myeloproliferative neoplasm	5
Prostate cancer	4
Bowel cancer	4
Gastrointestinal stromal tumour	1
Hepatocellular carcinoma	1
Cervical cancer	1
Nasopharyngeal cancer	1
Germ cell tumour	1
Ovarian cancer	1
Oesophageal cancer	1
Acute lymphoblastic leukemia	1
Bladder cancer	1
Myelodysplastic syndrome	1
2+ prior malignancies	7